PE20120817A1 - Peptidos tau antigenicos y usos de los mismos - Google Patents
Peptidos tau antigenicos y usos de los mismosInfo
- Publication number
- PE20120817A1 PE20120817A1 PE2012000116A PE2012000116A PE20120817A1 PE 20120817 A1 PE20120817 A1 PE 20120817A1 PE 2012000116 A PE2012000116 A PE 2012000116A PE 2012000116 A PE2012000116 A PE 2012000116A PE 20120817 A1 PE20120817 A1 PE 20120817A1
- Authority
- PE
- Peru
- Prior art keywords
- sequence
- seq
- amino acids
- vlp
- immunogen
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
Abstract
SE REFIERE A UN INMUNOGENO QUE COMPRENDE UN PEPTIDO TAU ANTIGENO QUE COMPRENDE UNA SECUENCIA DE AMINOACIDOS DE SEC ID Nº: 4, 6 A 26, 105 Y 108 A 112 QUE SE UNE COVALENTEMENTE A UN VEHICULO INMUNOGENICO POR UN ENGARCE QUE ESTA EN EL EXTREMO C-TERMINAL O N-TERMINAL, EN DONDE EL VEHICULO INMUNOGENICO ES UNA PARTICULA SIMILAR A VIRUS TAL COMO VLP DE HBcAg, VLP DE HBsAg Y VLP DE Qbeta. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA UTIL EN EL TRATAMIENTO DE LA ENFERMEDAD DE ALZHEIMER QUE COMPRENDE AL MENOS DOS INMUNOGENOS CADA UNO COMPUESTO POR UN PEPTIDO TAU ANTIGENO UNIDO A UN VEHICULO, EN DONDE i) EL PRIMER INMUNOGENO COMPRENDE LA SECUENCIA DE AMINOACIDOS DE SEC ID Nº: 4 Y 6 A 13; ii) EL SEGUNDO INMUNOGENO COMPRENDE LA SECUENCIA DE AMINOACIDOS DE SEC ID Nº: 14 A 19; iii) EL TERCER INMUNOGENO COMPRENDE LA SECUENCIA DE AMINOACIDOS DE SEC ID Nº: 20 A 24; Y iv) EL CUARTO INMUNOGENO COMPRENDE LA SECUENCIA DE AMINOACIDOS DE SEC ID Nº: 105 Y 108 A 112
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22986009P | 2009-07-30 | 2009-07-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20120817A1 true PE20120817A1 (es) | 2012-07-07 |
Family
ID=42941871
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2012000116A PE20120817A1 (es) | 2009-07-30 | 2010-07-20 | Peptidos tau antigenicos y usos de los mismos |
Country Status (17)
Country | Link |
---|---|
US (1) | US20110177109A1 (es) |
EP (1) | EP2459214A1 (es) |
JP (1) | JP2013500326A (es) |
KR (2) | KR20120049900A (es) |
CN (1) | CN102596236B (es) |
AR (1) | AR078085A1 (es) |
AU (1) | AU2010277254B2 (es) |
CA (1) | CA2768346A1 (es) |
CO (1) | CO6612199A2 (es) |
IN (1) | IN2012DN00446A (es) |
MX (1) | MX2012001194A (es) |
NZ (2) | NZ618391A (es) |
PE (1) | PE20120817A1 (es) |
RU (2) | RU2518291C2 (es) |
SG (1) | SG177637A1 (es) |
TW (2) | TW201436804A (es) |
WO (1) | WO2011013034A1 (es) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2572563T3 (es) | 2008-12-09 | 2016-06-01 | Coley Pharmaceutical Group, Inc. | Oligonucleótidos inmunoestimulantes |
US8552165B2 (en) * | 2008-12-09 | 2013-10-08 | Heather Davis | Immunostimulatory oligonucleotides |
UA107571C2 (xx) | 2009-04-03 | 2015-01-26 | Фармацевтична композиція | |
CN106390107B (zh) | 2009-06-10 | 2019-12-31 | 纽约大学 | 病理tau蛋白的免疫靶向 |
AU2013205313B2 (en) * | 2010-10-07 | 2016-05-19 | Ac Immune S.A. | Phosphospecific antibodies recognising tau |
HUE027649T2 (en) | 2010-10-07 | 2016-10-28 | Ac Immune Sa | Phosphonus recognition antibodies |
CA2826286C (en) | 2011-01-31 | 2021-09-21 | Intellect Neurosciences Inc. | Treatment of tauopathies |
MX339762B (es) | 2011-09-28 | 2016-05-27 | Univ Autonoma Del Estado De Morelos | Metalopeptidos inmunomoduladores (immp) y composiciones que los contienen. |
BR122021017560B1 (pt) | 2011-10-07 | 2023-03-07 | Katholieke Universiteit Leuven | Anticorpo, polinucleotídeo, composição farmacêutica, usos de um anticorpo, método in vitro, método de detecção post-mortem de multimêros do fosfo-tau, método de detecção in vitro da formação de um complexo imunológico, kits de teste, linhagem celular isolada e método de detecção in vitro de multimêros de fosfo-tau |
JP6293731B2 (ja) | 2012-04-05 | 2018-03-14 | エーシー イミューン エス.エー. | ヒト化タウ抗体 |
KR102494798B1 (ko) * | 2012-07-03 | 2023-02-06 | 워싱턴 유니버시티 | Tau에 대한 항체 |
SI2885010T1 (sl) | 2012-08-16 | 2020-07-31 | Ipierian, Inc. | Metode zdravljenja tauopatije |
US8980270B2 (en) | 2013-01-18 | 2015-03-17 | Ipierian, Inc. | Methods of treating a tauopathy |
BR112015023262B8 (pt) | 2013-03-15 | 2024-02-06 | Ac Immune Sa | Anticorpo isolado, imunoconjugado, formulação farmacêutica e usos do anticorpo |
WO2015017280A1 (en) * | 2013-07-28 | 2015-02-05 | Qantu Therapeutics, Inc. | Vaccine formulations that induce a th2 immune response |
WO2015122922A1 (en) | 2014-02-14 | 2015-08-20 | Ipierian, Inc. | Tau peptides, anti-tau antibodies, and methods of use thereof |
TWI734975B (zh) | 2014-06-27 | 2021-08-01 | 美商C2N醫療診斷有限責任公司 | 人類化抗-tau抗體 |
EP3166688A4 (en) | 2014-07-08 | 2017-12-20 | New York University | Tau imaging ligands and their uses in the diagnosis and treatment of tauopathy |
WO2016154522A1 (en) * | 2015-03-25 | 2016-09-29 | Stc. Unm | Immunotherapy compositions and methods for treatment of tauopathy and transgenic mouse |
MA42380A (fr) | 2015-07-06 | 2018-05-16 | Ucb Biopharma Sprl | Anticorps se liant à tau |
US10988528B2 (en) | 2015-08-13 | 2021-04-27 | New York University | Antibody-based molecules specific for the truncated ASP421 epitope of Tau and their uses in the diagnosis and treatment of tauopathy |
US11884707B2 (en) | 2016-09-29 | 2024-01-30 | Regeneron Pharmaceuticals, Inc. | Compositions for detection, inhibition and imaging of indoleamine 2, 3-dioxygenase 1 (IDO1) and methods of making and using same |
GB201700487D0 (en) | 2017-01-11 | 2017-02-22 | Hermon-Taylor John | Diagnostic |
EP3700556A2 (en) | 2017-10-25 | 2020-09-02 | Janssen Pharmaceuticals, Inc. | Compositions of phosphorylated tau peptides and uses thereof |
CN111405908A (zh) | 2017-10-27 | 2020-07-10 | 联脑科学公司 | Tau肽免疫原构建体 |
CN109870581B (zh) * | 2017-12-04 | 2021-05-04 | 厦门万泰凯瑞生物技术有限公司 | 一种定量检测HBsAg的试剂盒及方法 |
CN108314737B (zh) * | 2018-01-25 | 2021-03-16 | 中国科学院过程工程研究所 | 一种重组蛋白及其制备方法和应用 |
CN110548135B (zh) * | 2018-05-31 | 2023-06-06 | 长春百克生物科技股份公司 | 磷酸化多肽抗原疫苗及其制备方法和应用 |
US20230051538A1 (en) * | 2018-10-07 | 2023-02-16 | The University Of British Columbia | Conformation-specific epitopes in alpha-synuclein, antibodies thereto and methods related thereof |
CN113710269A (zh) | 2019-02-08 | 2021-11-26 | Ac免疫有限公司 | 磷酸化Tau肽疫苗的安全施用方法 |
WO2020186091A1 (en) * | 2019-03-12 | 2020-09-17 | Indi Molecular, Inc. | Cross-linked epitopes and methods of use thereof |
JP2022528953A (ja) | 2019-04-05 | 2022-06-16 | タウク3 バイオロジクス リミテッド | 抗タウc3抗体及びその使用 |
EP3965817A4 (en) | 2019-04-24 | 2023-11-22 | Janssen Pharmaceuticals, Inc. | HETEROLOGUE ADMINISTRATION OF TAU VACCINES |
GB2585252A (en) * | 2019-07-05 | 2021-01-06 | Gen2 Neuroscience Ltd | Tau epitope and binding molecules |
EP4212172A1 (en) * | 2020-09-08 | 2023-07-19 | Osaka University | Immunogenic composition targeting phosphorylated tau protein |
WO2023038548A1 (ru) * | 2021-09-08 | 2023-03-16 | Акционерное общество "БИОКАД" | Биспецифическое антитело, содержащее гетеродимер на основе мнс белков |
AU2022356435A1 (en) * | 2021-09-29 | 2024-03-28 | Ac Immune Sa | Method of safe administration of tau phosphopeptide conjugate |
CN115894659B (zh) * | 2022-10-19 | 2023-11-10 | 上海优宁维生物科技股份有限公司 | 微管相关蛋白Tau抗原及其制备方法和应用 |
Family Cites Families (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4469863A (en) | 1980-11-12 | 1984-09-04 | Ts O Paul O P | Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof |
US5023243A (en) | 1981-10-23 | 1991-06-11 | Molecular Biosystems, Inc. | Oligonucleotide therapeutic agent and method of making same |
DE3280400D1 (de) | 1981-10-23 | 1992-06-04 | Molecular Biosystems Inc | Oligonukleotides heilmittel und dessen herstellungsverfahren. |
US4722840A (en) | 1984-09-12 | 1988-02-02 | Chiron Corporation | Hybrid particle immunogens |
DE3525624A1 (de) | 1985-07-18 | 1987-01-22 | Celamerck Gmbh & Co Kg | Insektizid wirksames mittel zur bekaempfung von textilschaedlingen |
US5374426A (en) | 1986-09-03 | 1994-12-20 | University Of Saskatchewan | Rotavirus nucleocapsid protein VP6 in vaccine compositions |
GB8815795D0 (en) | 1988-07-02 | 1988-08-10 | Bkl Extrusions Ltd | Glazing bead |
NZ230747A (en) | 1988-09-30 | 1992-05-26 | Bror Morein | Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina |
HU212924B (en) | 1989-05-25 | 1996-12-30 | Chiron Corp | Adjuvant formulation comprising a submicron oil droplet emulsion |
NZ235315A (en) | 1989-09-19 | 1991-09-25 | Wellcome Found | Chimaeric hepadnavirus core antigen proteins and their construction |
SE466259B (sv) | 1990-05-31 | 1992-01-20 | Arne Forsgren | Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal |
AU9052091A (en) | 1990-12-20 | 1992-07-22 | Smithkline Beecham Biologicals (Sa) | Vaccines based on hepatitis b surface antigen |
US7408027B1 (en) * | 1991-12-06 | 2008-08-05 | Max-Planck-Gesellschaft Zur Forderung Der Wissenchaften | Tools for the diagnosis and treatment of Alzheimer's disease |
EP0544942A1 (en) * | 1991-12-06 | 1993-06-09 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Novel tools for the diagnosis and treatment of Alzheimer disease |
DE69230148T2 (de) * | 1991-12-06 | 2000-05-04 | Max Planck Gesellschaft | Werkzeuge für die Diagnose und Behandlung der Alzheimerschen Krankheit. |
SG49909A1 (en) | 1992-06-25 | 1998-06-15 | Smithkline Beecham Biolog | Vaccine composition containing adjuvants |
CN1087176C (zh) | 1993-03-23 | 2002-07-10 | 史密斯克莱·比奇曼生物公司 | 含有3-o脱酰基单磷酰脂a的疫苗制剂 |
DE4321946A1 (de) | 1993-07-01 | 1995-01-12 | Hoechst Ag | Methylphosphonsäureester, Verfahren zu deren Herstellung und deren Verwendung |
GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
US5658738A (en) | 1994-05-31 | 1997-08-19 | Becton Dickinson And Company | Bi-directional oligonucleotides that bind thrombin |
US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
PT772619E (pt) | 1994-07-15 | 2006-10-31 | Univ Iowa Res Found | Oligonucleotidos imunomoduladores |
US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
WO1996030523A2 (en) | 1995-03-31 | 1996-10-03 | Hans Wolf | Antigen presentation system based on retrovirus-like particles |
GB9513261D0 (en) | 1995-06-29 | 1995-09-06 | Smithkline Beecham Biolog | Vaccines |
WO1997034145A1 (fr) * | 1996-03-13 | 1997-09-18 | Mitsubishi Chemical Corporation | Anticorps a proteine tau antiphosphorylee et procede de detection de la maladie d'alzheimer l'utilisant |
GB9621091D0 (en) | 1996-10-09 | 1996-11-27 | Fondation Pour Le Perfectionem | Attenuated microorganisms strains and their uses |
CA2268825C (en) | 1996-10-11 | 2006-04-18 | The Regents Of The University Of California | Immunostimulatory polynucleotide/immunomodulatory molecule conjugates |
WO1998022120A1 (en) * | 1996-11-19 | 1998-05-28 | The Wistar Institute Of Anatomy & Biology | Diagnostic and therapeutic reagents for alzheimer's disease |
AUPO517897A0 (en) | 1997-02-19 | 1997-04-11 | Csl Limited | Chelating immunostimulating complexes |
JP2001513776A (ja) | 1997-02-28 | 2001-09-04 | ユニバーシティ オブ アイオワ リサーチ ファウンデーション | LPS関連障害の処置における非メチル化CpGジヌクレオチドを含む核酸の使用 |
DK1005368T3 (da) | 1997-03-10 | 2010-01-04 | Ottawa Hospital Res Inst | Anvendelse af nukleinsyrer, der indeholder ikke-metyleret CpG dinukleotid i kombination med alun som hjælpestoffer |
AU7690898A (en) | 1997-05-20 | 1998-12-11 | Ottawa Civic Hospital Loeb Research Institute | Vectors and methods for immunization or therapeutic protocols |
JP4101888B2 (ja) | 1997-06-06 | 2008-06-18 | ダイナバックス テクノロジーズ コーポレイション | 免疫刺激オリゴヌクレオチド、その組成物およびその使用方法 |
GB9712347D0 (en) | 1997-06-14 | 1997-08-13 | Smithkline Beecham Biolog | Vaccine |
GB9717953D0 (en) | 1997-08-22 | 1997-10-29 | Smithkline Beecham Biolog | Vaccine |
EP1279401B1 (en) | 1997-09-05 | 2008-01-09 | GlaxoSmithKline Biologicals S.A. | Oil in water emulsions containing saponins |
ID26669A (id) | 1998-02-12 | 2001-01-25 | Immune Complex Corp | Inti protein-protein hepatitis b yang dimodifikasi secara strategi dan turunan-turunannya |
US6303114B1 (en) | 1998-03-05 | 2001-10-16 | The Medical College Of Ohio | IL-12 enhancement of immune responses to T-independent antigens |
AU746163B2 (en) | 1998-04-09 | 2002-04-18 | Smithkline Beecham Biologicals (Sa) | Adjuvant compositions |
GB9817052D0 (en) | 1998-08-05 | 1998-09-30 | Smithkline Beecham Biolog | Vaccine |
TR200101055T2 (tr) | 1998-10-16 | 2001-09-21 | Smithkline Beecham Biologicals S.A. | Adjuvan sistemler ve aşılar |
JP4486257B2 (ja) | 1998-10-21 | 2010-06-23 | アメリカ合衆国 | 自己抗体の誘導のためのウイルス様粒子 |
ATE315658T1 (de) | 1998-11-05 | 2006-02-15 | Powderject Vaccines Inc | Genkonstrukte für genimmunisierung |
WO2000032227A2 (en) | 1998-11-30 | 2000-06-08 | Cytos Biotechnology Ag | Ordered molecular presentation of antigens, method of preparation and use |
AUPP807399A0 (en) | 1999-01-08 | 1999-02-04 | Csl Limited | Improved immunogenic lhrh composition and methods relating thereto |
ATE464907T1 (de) | 1999-02-17 | 2010-05-15 | Csl Ltd | Immunogene komplexe und methoden in bezug auf diese |
SI1162999T1 (sl) | 1999-03-19 | 2007-04-30 | Glaxosmithkline Biolog Sa | Vakcina proti Streptococcus pneumoniae |
ES2228497T3 (es) | 1999-04-19 | 2005-04-16 | Glaxosmithkline Biologicals S.A. | Composicion adyuvante que comprende saponina y un oligonucleotido inmunoestimulante. |
MXPA02003067A (es) | 1999-09-24 | 2002-09-30 | Smithkline Beecham Biolog | Uso de combinacion de ester sorbitano de polioxietileno y octoxinol como adjuvante y su uso en vacunas. |
AR025749A1 (es) | 1999-09-24 | 2002-12-11 | Smithkline Beecham Biolog | Vacunas |
MXPA02009895A (es) | 2000-04-07 | 2004-09-06 | Univ Leeds Innovations Ltd | Proteinas de fusion de antigeno de nucleo de hepatitis b. |
WO2001085208A2 (en) | 2000-05-05 | 2001-11-15 | Cytos Biotechnology Ag | Molecular antigen arrays and vaccines |
AU6616301A (en) | 2000-06-22 | 2002-01-02 | Celltech Pharmaceuticals Ltd | Modification of hepatitis b core antigen |
EP1304947A1 (en) | 2000-07-15 | 2003-05-02 | Lighthouse Display International Limited | Shelf edge display fittings |
AUPQ912000A0 (en) | 2000-07-31 | 2000-08-24 | Crown In The Right Of The Queensland Department Of Health, The | Improved virus like particles |
US20030138769A1 (en) | 2000-08-16 | 2003-07-24 | Birkett Ashley J. | Immunogenic HBc chimer particles having enhanced stability |
US7320793B2 (en) * | 2001-01-19 | 2008-01-22 | Cytos Biotechnology Ag | Molecular antigen array |
WO2003102165A2 (en) | 2002-02-21 | 2003-12-11 | Apovia, Inc. | IMMUNOGENIC HBc CHIMER PARTICLES STABILIZED WITH AN N-TERMINAL CYSTEINE |
ES2335979T3 (es) | 2001-09-14 | 2010-04-07 | Cytos Biotechnology Ag | Empaquetamiento de cpg inmunoestimuladores en particulas similares a virus: metodo de preparacion y su uso. |
AU2002347404A1 (en) | 2001-09-14 | 2003-04-01 | Cytos Biotechnology Ag | In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles |
US20040176283A1 (en) | 2002-04-01 | 2004-09-09 | Robinson John A. | Methods and compositions for the design of synthetic vaccines |
GB0209878D0 (en) | 2002-04-30 | 2002-06-05 | Glaxosmithkline Biolog Sa | Vaccine |
US7138252B2 (en) | 2002-07-17 | 2006-11-21 | Cytos Biotechnology Ag | Molecular antigen arrays |
DE60336902D1 (de) * | 2002-07-19 | 2011-06-09 | Cytos Biotechnology Ag | Impfstoffzusammensetzungen enthaltende amyloid beta 1-6 antigenarrays |
KR100991679B1 (ko) | 2002-12-10 | 2010-11-04 | 셀덱스 테라퓨틱스 리미티드 | 안정화 면역원성 HBc 키메라 입자 |
SG149013A1 (en) * | 2003-12-17 | 2009-01-29 | Wyeth Corp | Immunogenic peptide carrier conjugates and methods of producing same |
EP2484374A1 (en) | 2004-07-18 | 2012-08-08 | CSL Limited | Immuno stimulating complex and oligonucleotide formulations for inducing enhanced interferon-gamma responses |
US20070129320A9 (en) | 2004-07-18 | 2007-06-07 | Coley Pharmaceutical Group, Ltd. | Methods and compositions for inducing innate immune responses |
WO2006040153A2 (en) * | 2004-10-13 | 2006-04-20 | Ablynx N.V. | Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease |
US8012936B2 (en) * | 2006-03-29 | 2011-09-06 | New York University | Tau fragments for immunotherapy |
DE602006015421D1 (de) * | 2006-04-13 | 2010-08-26 | Bio Life Science Forschungs & Entwicklungsgesellschaft Mbh | HER-2/neu Multipeptidimpfstoff |
US20080166785A1 (en) | 2006-08-16 | 2008-07-10 | Monica Sala-Schaeffer | Polynucleotides allowing the expression and secretion of recombinant HBsAg virus-like particles containing a foreign peptide, their production and use |
CN106390107B (zh) * | 2009-06-10 | 2019-12-31 | 纽约大学 | 病理tau蛋白的免疫靶向 |
-
2010
- 2010-07-20 NZ NZ618391A patent/NZ618391A/en not_active IP Right Cessation
- 2010-07-20 IN IN446DEN2012 patent/IN2012DN00446A/en unknown
- 2010-07-20 MX MX2012001194A patent/MX2012001194A/es not_active Application Discontinuation
- 2010-07-20 PE PE2012000116A patent/PE20120817A1/es not_active Application Discontinuation
- 2010-07-20 WO PCT/IB2010/053313 patent/WO2011013034A1/en active Application Filing
- 2010-07-20 CN CN201080040148.8A patent/CN102596236B/zh not_active Expired - Fee Related
- 2010-07-20 SG SG2012002390A patent/SG177637A1/en unknown
- 2010-07-20 EP EP10739402A patent/EP2459214A1/en not_active Withdrawn
- 2010-07-20 KR KR1020127005415A patent/KR20120049900A/ko active IP Right Grant
- 2010-07-20 JP JP2012522292A patent/JP2013500326A/ja active Pending
- 2010-07-20 KR KR1020137028550A patent/KR20130127547A/ko not_active Application Discontinuation
- 2010-07-20 AU AU2010277254A patent/AU2010277254B2/en not_active Ceased
- 2010-07-20 RU RU2012102701/10A patent/RU2518291C2/ru not_active IP Right Cessation
- 2010-07-20 NZ NZ598356A patent/NZ598356A/en not_active IP Right Cessation
- 2010-07-20 CA CA2768346A patent/CA2768346A1/en not_active Abandoned
- 2010-07-29 TW TW103104138A patent/TW201436804A/zh unknown
- 2010-07-29 AR ARP100102753A patent/AR078085A1/es unknown
- 2010-07-29 US US12/846,719 patent/US20110177109A1/en not_active Abandoned
- 2010-07-29 TW TW099125165A patent/TWI461209B/zh not_active IP Right Cessation
-
2012
- 2012-02-15 CO CO12026764A patent/CO6612199A2/es unknown
-
2014
- 2014-03-31 RU RU2014112002/10A patent/RU2014112002A/ru not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
US20110177109A1 (en) | 2011-07-21 |
RU2012102701A (ru) | 2013-09-10 |
TWI461209B (zh) | 2014-11-21 |
RU2518291C2 (ru) | 2014-06-10 |
TW201106968A (en) | 2011-03-01 |
SG177637A1 (en) | 2012-03-29 |
AU2010277254B2 (en) | 2015-05-07 |
CO6612199A2 (es) | 2013-02-01 |
RU2014112002A (ru) | 2015-10-10 |
WO2011013034A1 (en) | 2011-02-03 |
MX2012001194A (es) | 2012-03-07 |
EP2459214A1 (en) | 2012-06-06 |
CA2768346A1 (en) | 2011-02-03 |
AR078085A1 (es) | 2011-10-12 |
KR20120049900A (ko) | 2012-05-17 |
CN102596236B (zh) | 2015-06-24 |
NZ618391A (en) | 2015-07-31 |
JP2013500326A (ja) | 2013-01-07 |
WO2011013034A4 (en) | 2011-04-28 |
NZ598356A (en) | 2014-06-27 |
IN2012DN00446A (es) | 2015-05-15 |
TW201436804A (zh) | 2014-10-01 |
KR20130127547A (ko) | 2013-11-22 |
AU2010277254A1 (en) | 2012-02-09 |
CN102596236A (zh) | 2012-07-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20120817A1 (es) | Peptidos tau antigenicos y usos de los mismos | |
PE20110891A1 (es) | Vacuna de peptido ch3 de ige | |
PE20161560A1 (es) | Vacuna de pcsk9 | |
HRP20161710T1 (hr) | Identifikacija, optimizacija i uporaba kriptičkih hla-a24 etiopa za imunoterapiju | |
RU2021132097A (ru) | Белки rsv f в предшествующей слиянию конформации и их применение | |
PE20190352A1 (es) | Proteinas de fusion gdf 15 y usos de estas | |
RU2020132040A (ru) | Общие неоантигены | |
AR064642A1 (es) | Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi | |
RU2492182C3 (ru) | ГИДРОФОБНЫЕ, МОДИФИЦИРОВАННЫЕ, ПОЛУЧЕННЫЕ ИЗ preS ВИРУСА ГЕПАТИТА В (HBV) ПЕПТИДЫ И ИХ ИСПОЛЬЗОВАНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ ПРОНИКНОВЕНИЯ HBV И HDV | |
NZ702145A (en) | Bluetongue virus recombinant vaccines and uses thereof | |
ES2454773T3 (es) | Fragmentos solubles de la proteína PB2 del virus influenza con capacidad para unirse a un casquete de ARN | |
RU2017135038A (ru) | Пептид, полученный из gpc3, фармацевтическая композиция для лечения или предотвращения рака с его использованием, индуктор иммунитета и способ получения антиген-презентирующих клеток | |
JP2015509707A5 (es) | ||
EA201491277A1 (ru) | Противораковый слитый белок | |
JP2012525410A5 (es) | ||
EP2661442A1 (en) | Monomeric and multimeric immunogenic peptides | |
JP2012102105A5 (es) | ||
GB2598494A (en) | A subunit vaccine for treatment or prevention of a respiratory tract infection | |
Gunay et al. | Peptide aggregation induced immunogenic rupture (PAIIR) | |
BR112018003580A2 (pt) | molécula de ácido nucléico, método para apresentar um polipeptídeo alvo, proteína recombinante, partícula do tipo viral, composição farmacêutica, polipeptídeo, vetor, célula hospedeira e método para preparar a proteína recombinante | |
JP2018501258A5 (es) | ||
TW201008576A (en) | New fusion proteins and their use for the preparation of vaccines against hepatitis C | |
RU2010126154A (ru) | Эпитопные пептиды stat3 | |
RU2015140603A (ru) | Вакцины на основе нуклеопротеина вируса гриппа | |
RU2009115688A (ru) | Иммуногенные гибридные полипептиды против ожирения и композиция вакцин против ожирения, содержащая эти полипептиды |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |